Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

Entrada has secured the authorisation within the EU Clinical Trial Regulation to begin the Phase I/II trial of ENTR-601-45.

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

WCG has launched the WCG Study Accelerator, an integrated solution designed to optimise the clinical trial process.

Pfizer’s and Arvinas’ vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) ER degrader which slows tumour growth.

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

The US-based START Center for Cancer Research (START) and OneOncology have collaborated to introduce three early-phase trial ...

Rein Therapeutics has dosed the first subject in a Phase II trial of LTI-03, its lead asset for treating idiopathic pulmonary ...

Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a ...

Gilgamesh managed to overcome the issue of functional unblinding in the study, an obstacle experienced by the psychedelic ...

The 12th Outsourcing in Clinical Trials UK & Ireland conference will focus on the region’s future as a clinical trials hub.